Epstein-Barr virus presence in pediatric diffuse large B-cell lymphoma reveals a particular association and latency patterns: Analysis of viral role in tumor microenvironment

International Journal of Cancer

Volumn 132, Issue 7, 2013, Pages 1572-1580

  Cohen, Melina ^a   De Matteo, Elena ^a   Narbaitz, Marina ^b   Carreño, Fernanda Agost ^b   Preciado, Maria V ^a   Chabay, Paola A ^a  

^a HOSPITAL DE NIÑOS RICARDO GUTIÉRREZ   (Argentina)

^b ACADEMIA NACIONAL DE MEDICINA   (Argentina)

Author keywords

childhood; diffuse large B cell lymphoma; Epstein Barr virus; Epstein Barr virus latency pattern; T cell markers

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; FORMALDEHYDE; LATENT MEMBRANE PROTEIN 1; LATENT MEMBRANE PROTEIN 2A; PARAFFIN; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADOLESCENT; ANTIGEN EXPRESSION; ARGENTINA; ARTICLE; BZLF1 LYTIC GENE; CANCER PATIENT; CELL NUCLEUS; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; EMBEDDING; EPSTEIN BARR VIRUS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE DEFICIENCY; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INCIDENCE; LARGE CELL LYMPHOMA; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE SUBPOPULATION; TISSUE FIXATION; TUMOR BIOPSY; TUMOR MICROENVIRONMENT; VIRUS GENE; VIRUS LATENCY;

ADOLESCENT; ARGENTINA; CHILD; CHILD, PRESCHOOL; EPSTEIN-BARR VIRUS INFECTIONS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; FEMALE; FOLLOW-UP STUDIES; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; PREVALENCE; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, VIRAL; T-LYMPHOCYTE SUBSETS; TUMOR MICROENVIRONMENT; VIRAL LOAD; VIRAL MATRIX PROTEINS; VIRUS LATENCY;

EID: 84873077305     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27845     Document Type: Article

References (50)

1. Oschlies I, Klapper W, Zimmermann M, et al. Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial. Blood 2006; 107: 4047-52.
2. Burkhardt B, Zimmermann M, Oschlies I, et al. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol 2005; 131: 39-49.
3. Wood WA, Lee SJ,. Malignant hematologic diseases in adolescents and young adults. Blood 2011; 117: 5803-15.
4. ROHA. Registro Oncopediátrico Hospitalario Argentino. Resultados 2000-2008., 3rd edn., Buenos Aires: Fundaciõn Kaleidos, 2010.
5. Rickinson AB, Kieff ED,. Epstein Barr virus. In:, Knipe DM, Howley PM, eds. Fields virology, 5th edn., vol. 2. Philadelphia: Walters Kluwers/Lippincott Williams & Wilkins, 2007. 2655-700.
6. Young LS, Rickinson AB,. Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004; 4: 757-68.
7. IARC. WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn., vol. 2. Lyon: WHO Press, 2008.
8. Adam P, Bonzheim I, Fend F, et al. Epstein-Barr virus-positive diffuse large B-cell lymphomas of the elderly. Adv Anat Pathol 2011; 18: 349-55.
9. Beltran BE, Castillo JJ, Morales D, et al. EBV-positive diffuse large B-cell lymphoma of the elderly: a case series from Peru. Am J Hematol 2011; 86: 663-7.
10. Hofscheier A, Ponciano A, Bonzheim I, et al. Geographic variation in the prevalence of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly: a comparative analysis of a Mexican and a German population. Mod Pathol 2011; 24: 1046-54.
11. Oyama T, Yamamoto K, Asano N, et al. Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. Clin Cancer Res 2007; 13: 5124-32.
12. Gibson SE, Hsi ED,. Epstein-Barr virus-positive B-cell lymphoma of the elderly at a United States tertiary medical center: an uncommon aggressive lymphoma with a nongerminal center B-cell phenotype. Hum Pathol 2009; 40: 653-61.
13. Hoeller S, Tzankov A, Pileri SA, et al. Epstein-Barr virus-positive diffuse large B-cell lymphoma in elderly patients is rare in Western populations. Hum Pathol 2010; 41: 352-7.
14. Castillo JJ, Beltran BE, Miranda RN, et al. Epstein-barr virus-positive diffuse large B-cell lymphoma of the elderly: what we know so far. Oncologist 2011; 16: 87-96.
15. Park S, Lee J, Ko YH, et al. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood 2007; 110: 972-8.
16. Cacciatore M, Guarnotta C, Calvaruso C, et al. Microenvironment-centred dynamics in aggressive B-cell lymphomas. Adv Hematol, 2012; 2012: 138079.
17. de Jong D, Enblad G,. Inflammatory cells and immune microenvironment in malignant lymphoma. J Intern Med 2008; 264: 528-36.
18. Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008; 359: 2313-23.
19. Linderoth J, Eden P, Ehinger M, et al. Genes associated with the tumour microenvironment are differentially expressed in cured versus primary chemotherapy-refractory diffuse large B-cell lymphoma. Br J Haematol 2008; 141: 423-32.
20. Barros MH, Vera-Lozada G, Soares FA, et al. Tumor microenvironment composition in pediatric classical Hodgkin lymphoma is modulated by age and Epstein-Barr virus infection. Int J Cancer 2012; 131: 1142-52.
21. Baumforth KR, Birgersdotter A, Reynolds GM, et al. Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin's lymphoma cells mediates up-regulation of CCL20 and the migration of regulatory T cells. Am J Pathol 2008; 173: 195-204.
22. Chetaille B, Bertucci F, Finetti P, et al. Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood 2009; 113: 2765-3775.
23. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-82.
24. Pfaffl MW,. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29: e45.
25. Kim JM, Rudensky A,. The role of the transcription factor Foxp3 in the development of regulatory T cells. Immunol Rev 2006; 212: 86-98.
26. Cool CD, Bitter MA,. The malignant lymphomas of Kenya: morphology, immunophenotype, and frequency of Epstein-Barr virus in 73 cases. Hum Pathol 1997; 28: 1026-33.
27. Tumwine LK, Orem J, Kerchan P, et al. EBV, HHV8 and HIV in B cell non Hodgkin lymphoma in Kampala, Uganda. Infect Agent Cancer 2010; 5: 12.
28. Chabay PA, Barros MH, Hassan R, et al. Pediatric Hodgkin lymphoma in 2 South American series: a distinctive epidemiologic pattern and lack of association of Epstein-Barr virus with clinical outcome. J Pediatr Hematol Oncol 2008; 30: 285-91.
29. Chabay P, Lara J, Lorenzetti M, et al. Epstein Barr virus in relation to apoptosis markers and patients' outcome in pediatric B-cell non-Hodgkin lymphoma. Cancer Lett 2011; 307: 221-6.
30. Chabay P, Burna V, Moar A, et al. Prevalencia de la infeccion por el virus de Epstein Barr en pacientes pediatricos. Rev Hosp Ninos 1999; 41: 88-91.
31. Hsu JL, Glaser SL,. Epstein-barr virus-associated malignancies: epidemiologic patterns and etiologic implications. Crit Rev Oncol Hematol 2000; 34: 27-53.
32. Chabay PA, De Matteo EN, Aversa L, et al. Assessment of Epstein-Barr virus association with pediatric non-hodgkin lymphoma in immunocompetent and in immunocompromised patients in Argentina. Arch Pathol Lab Med 2002; 126: 331-5.
33. Sandlund JT, Downing JR, Crist WM,. Non-Hodgkin's lymphoma in childhood. N Engl J Med 1996; 334: 1238-48.
34. Nadal D, Caduff R, Frey E, et al. Non-Hodgkin's lymphoma in four children infected with the human immunodeficiency virus. Association with Epstein-Barr Virus and treatment. Cancer 1994; 73: 224-30.
35. Preciado MV, Fallo A, Chabay P, et al. Epstein Barr virus-associated lymphoma in HIV-infected children. Pathol Res Pract 2002; 198: 327-32.
36. Anderton E, Yee J, Smith P, et al. Two Epstein-Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor Bim: clues to the pathogenesis of Burkitt's lymphoma. Oncogene 2008; 27: 421-33.
37. Kasprzak A, Spachacz R, Wachowiak J, et al. Epstein-Barr virus (EBV) infection in B-cell non-Hodgkin's lymphomas in children: virus latency and its correlation with CD21 and CD23 molecules. Folia Histochem Cytobiol 2007; 45: 169-79.
38. Niedobitek G, Agathanggelou A, Rowe M, et al. Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma. Blood 1995; 86: 659-65.
39. Young LS, Dawson CW, Clark D, et al. Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol 1988; 69: 1051-65.
40. Nguyen-Van D, Keane C, Han E, et al. Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly expresses EBNA3A with conserved CD8+ T-cell epitopes. Am J Blood Res 2011; 1: 14.
41. Rowe M, Kelly GL, Bell AI, et al. Burkitt's lymphoma: the Rosetta Stone deciphering Epstein-Barr virus biology. Semin Cancer Biol 2009; 19: 377-88.
42. Johannsen E, Koh E, Mosialos G, et al. Epstein-Barr virus nuclear protein 2 transactivation of the latent membrane protein 1 promoter is mediated by J kappa and PU.1. J Virol 1995; 69: 253-62.
43. Kis LL, Gerasimcik N, Salamon D, et al. STAT6 signaling pathway activated by the cytokines IL-4 and IL-13 induces expression of the Epstein-Barr virus-encoded protein LMP-1 in absence of EBNA-2: implications for the type II EBV latent gene expression in Hodgkin lymphoma. Blood 2011; 117: 165-74.
44. Chapman AL, Rickinson AB, Thomas WA, et al. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy. Cancer Res 2001; 61: 6219-26.
45. Lee SP,. Nasopharyngeal carcinoma and the EBV-specific T cell response: prospects for immunotherapy. Semin Cancer Biol 2002; 12: 463-71.
46. Alvaro T, Lejeune M, Salvado MT, et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 2005; 11: 1467-73.
47. Lambert SL, Martinez OM,. Latent membrane protein 1 of EBV activates phosphatidylinositol 3-kinase to induce production of IL-10. J Immunol 2007; 179: 8225-34.
48. Mahot S, Sergeant A, Drouet E, et al. A novel function for the Epstein-Barr virus transcription factor EB1/Zta: induction of transcription of the hIL-10 gene. J Gen Virol 2003; 84: 965-74.
49. Samanta M, Iwakiri D, Takada K,. Epstein-Barr virus-encoded small RNA induces IL-10 through RIG-I-mediated IRF-3 signaling. Oncogene 2008; 27: 4150-60.
50. Oudejans JJ, Jiwa NM, Kummer JA, et al. Activated cytotoxic T cells as prognostic marker in Hodgkin's disease. Blood 1997; 89: 1376-82.